CNS Pharmaceuticals (CNSP) Operating Expenses (2018 - 2025)
CNS Pharmaceuticals' (CNSP) quarterly Operating Expenses came in at $6.0 million in Q4 2025, up 87.06% YoY from $3.2 million in Q4 2024, and up 84.0% on a QoQ basis from $3.3 million in Q3 2025.
CNS Pharmaceuticals (CNSP) Operating Expenses (2018 - 2025) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 8 years of Operating Expenses data on file, last reported at $6.0 million in Q4 2025.
- Quarterly Operating Expenses rose 87.06% year-over-year to $6.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.0 million (up 7.28% YoY) and the FY2025 annual result came in at $16.0 million, up 7.28% from the prior year.
- Operating Expenses grew to $6.0 million in Q4 2025, from $3.3 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $6.0 million in Q4 2025 to a low of $2.4 million in Q2 2025.
- A 5-year average of $4.0 million and a median of $3.7 million in 2021 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2021 — Operating Expenses surged 89.62% — and 2025, when it sank 42.2%.
- Tracing CNSP's Operating Expenses over 5 years: stood at $3.3 million in 2021, then soared by 57.91% to $5.1 million in 2022, then climbed by 4.77% to $5.4 million in 2023, then tumbled by 40.51% to $3.2 million in 2024, then soared by 87.06% to $6.0 million in 2025.
- The last three Operating Expenses figures came in at $6.0 million (Q4 2025), $3.3 million (Q3 2025), and $2.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 541.02 Mn |
| 10 | CNS Pharmaceuticals | 2.58 Mn | -4.62 Mn | - | 5.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.99 Mn |
| Sep 30, 2025 | 3.25 Mn |
| Jun 30, 2025 | 2.41 Mn |
| Mar 31, 2025 | 4.34 Mn |
| Dec 31, 2024 | 3.20 Mn |
| Sep 30, 2024 | 5.63 Mn |
| Jun 30, 2024 | 2.53 Mn |
| Mar 31, 2024 | 3.54 Mn |
| Dec 31, 2023 | 5.38 Mn |
| Sep 30, 2023 | 4.53 Mn |
| Jun 30, 2023 | 4.03 Mn |
| Mar 31, 2023 | 4.93 Mn |
| Dec 31, 2022 | 5.13 Mn |
| Sep 30, 2022 | 3.42 Mn |
| Jun 30, 2022 | 3.56 Mn |
| Mar 31, 2022 | 3.15 Mn |
| Dec 31, 2021 | 3.25 Mn |
| Sep 30, 2021 | 3.81 Mn |
| Jun 30, 2021 | 3.81 Mn |
| Mar 31, 2021 | 3.61 Mn |